$DCOY SEC Filings

Filed On	Filing
16 Oct 2026	EFFECT
16 Oct 2026	424B3
07 Oct 2026	S-1
23 Sep 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more Warrant Shares: 2,368,868 Initial Exercise Date: September 23, 2026
15 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders On September 14, 2026, Decoy Therapeutics Inc. (the “Company”) convened a Special Meeting of Stockholders (the “Special Meeting”). As of July 20, 2026, the record date for the Special Meeting, there were 590,185 shares of common stock is...
02 Sep 2026	Form 4: Lieber Jonathan I, Director Received 2,000 shares as a grant or award
02 Sep 2026	Form 4: Pierce Frederick Ii, Chief Executive Officer Received 33,455 shares as a grant or award
02 Sep 2026	Form 4: Marschel Peter Klaus, Chief Business Officer Received 3,900 shares as a grant or award
02 Sep 2026	Form 4: Rosenblum Mark J, Chief Financial Officer Received 9,682 shares as a grant or award
02 Sep 2026	Form 4: Hibner Barbara Louise, Chief Scientific Officer Received 4,216 shares as a grant or award
02 Sep 2026	Form 4: Hanish Arnold C, Director Received 3,000 shares as a grant or award
02 Sep 2026	Form 4: Lammers Paul, Director Received 2,000 shares as a grant or award
02 Sep 2026	Form 4: Burleson Tess, Director Received 2,000 shares as a grant or award
02 Sep 2026	Form 4: McVicar William K., Director Received 3,000 shares as a grant or award
02 Sep 2026	Form 4: Gauthier Patricia G., Director Received 2,000 shares as a grant or award
14 Aug 2026	SCHEDULE 13G
12 Aug 2026	10-Q
04 Aug 2026	Proxy statement: special meeting on September 14, 2026
04 Aug 2026	DEFA14A
31 Jul 2026	Form 3: Gauthier Patricia G., Director No securities owned

Comments